



RESOLVE THERAPEUTICS ANNOUNCES PUBLICATION OF CLINICAL DATA DEMONSTRATING THE ROLE OF CIRCULATING RNA IN SYSTEMIC LUPUS ERYTHEMATOSUS

Seattle, WA- (August 22, 2016) Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company developing potentially transformative therapies for the treatment of lupus and Sjögren’s syndrome, today announced the publication of a clinical study demonstrating the role of circulating RNA in systemic lupus erythematosus. The study entitled “Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus” was published online August 17 in *The Journal of Immunology* and can be found at (www.jimmunol.org/content/early/2016/08/17/jimmunol.1601142). “This study, for the first time to our knowledge, connects the dots between circulating RNA, interferon-regulated inflammatory pathways, and disease activity in a large cross section of lupus patients”, commented Dr. James Posada, Resolve’s founder and CEO.

About Resolve Therapeutics

Resolve Therapeutics is a privately held biotechnology company that is dedicated to improving the lives of patients with lupus and Sjögren’s syndrome through the development of its platform of targeted nuclease therapeutics. In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus, Sjögren’s syndrome and other autoimmune diseases. Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital. For more information on the company please visit: <http://www.resolvebio.com>.

###

Contact:

James Posada, Ph.D.
Chief Executive Officer
Resolve Therapeutics, LLC
(208) 727-7010
jp@resolvebio.com